<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838291</url>
  </required_header>
  <id_info>
    <org_study_id>LA35-PM</org_study_id>
    <nct_id>NCT01838291</nct_id>
  </id_info>
  <brief_title>Active Drug Surveillance Program of Ferriprox Use</brief_title>
  <official_title>Active Drug Surveillance Program of Ferriprox Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ApoPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, open label, prospective, multi-center, post-marketing drug surveillance
      program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A post-marketing, drug surveillance program evaluating the use, monitoring, benefits and
      adverse effects of Ferriprox under clinical conditions in newly treated patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of dose of Ferriprox, and if applicable concurrent chelator(s) in newly treated patients.</measure>
    <time_frame>Baseline to 12 Months</time_frame>
    <description>Evaluation of dose of Ferriprox includes the frequency of administration of chelator(s).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of regimen of Ferriprox administration, and if applicable concurrent chelator(s) in newly treated patients.</measure>
    <time_frame>Baseline to 12 Months</time_frame>
    <description>Evaluation of how Ferriprox is prescribed/received by the patient: as monotherapy, simultaneous with deferoxamine, alternate with deferoxamine, simultaneous with deferasirox, alternate with deferasirox.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the beneficial effects of Ferriprox based on the characterization of its use in clinical practice.</measure>
    <time_frame>Baseline to 12 Months</time_frame>
    <description>Beneficial effects of Ferriprox will be assessed based on the changes in: serum ferritin and cardiac iron concentration as assessed by MRI T2*.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the adverse effects of Ferriprox based on the characterization of its use in clinical practice.</measure>
    <time_frame>Baseline to 12 Months</time_frame>
    <description>Adverse effects of Ferriprox will be assessed based on: frequency of absolute neutrophil count (ANC) monitoring, occurrence of neutropenia or agranulocytosis and occurrence of other adverse events (AEs) or adverse drug reactions (ADRs).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">294</enrollment>
  <condition>Transfusional Iron Overload</condition>
  <arm_group>
    <arm_group_label>Patients on Ferriprox therapy &lt;1 month</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Apporximately 300 patients who have recently started treatment with treatment with
        Ferriprox (less than one month prior to enrolment) or who are naive to Ferriprox treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients who started Ferriprox therapy less than one month or are to initiate
             Ferriprox therapy at the time of enrolment into the program.

        Main Exclusion Criteria:

          -  Patients treated with Ferriprox for more than one month prior to enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Tricta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ApoPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thalassemia Center of North Cyprus Turkish Republic (KKTC)</name>
      <address>
        <city>Nicosia</city>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Unit, El-Shatby Children Hospital, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Unit, Assiut University Hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Unit, Mansoura University Children Hospital</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanta University Hospital</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Unit ; Zagazig University Children Hospital</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zagazig University; Thalassemia Association</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Child Health, College of Medicine and Health Sciences, Sultan Qaboos University Hospital</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz University Hospital (KAAUH)</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternity and Children's Hospital</name>
      <address>
        <city>Maddinah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Çukurova Üniversitesi Tip Fakültesi, Çocuk Hematolojie Bilim Dali</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz Üniversitesi Hastanesi, Çocuk Sağliği, Hematolojie Kliniği</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ïstanbul Üniversitesi Tip. Fak. Hastanesi, Çocuk Sağliği, Hematolojie Kliniği</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cyprus</country>
    <country>Egypt</country>
    <country>Oman</country>
    <country>Saudi Arabia</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ferriprox</keyword>
  <keyword>Deferiprone</keyword>
  <keyword>DFP</keyword>
  <keyword>L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

